Recent progress on gene-deleted live-attenuated African swine fever virus vaccines

Hiep L. X. Vu,D. Scott McVey

DOI: https://doi.org/10.1038/s41541-024-00845-9

2024-03-14

npj Vaccines

Abstract:African Swine Fever (ASF) is a highly lethal viral disease in swine, with mortality rates approaching 100%. The disease has spread to many swine-producing countries, leading to significant economic losses and adversely impacting global food security. Extensive efforts have been directed toward developing effective ASF vaccines. Among the vaccinology approaches tested to date, live-attenuated virus (LAV) vaccines produced by rational deleting virulence genes from virulent African Swine Fever Virus (ASFV) strains have demonstrated promising safety and efficacy in experimental and field conditions. Many gene-deleted LAV vaccine candidates have been generated in recent years. The virulence genes targeted for deletion from the genome of virulent ASFV strains can be categorized into four groups: Genes implicated in viral genome replication and transcription, genes from the multigene family located at both 5′ and 3′ termini, genes participating in mediating hemadsorption and putative cellular attachment factors, and novel genes with no known functions. Some promising LAV vaccine candidates are generated by deleting a single viral virulence gene, whereas others are generated by simultaneously deleting multiple genes. This article summarizes the recent progress in developing and characterizing gene-deleted LAV vaccine candidates.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The paper primarily discusses the progress in the development of gene-deleted live-attenuated vaccines (LAV) for African Swine Fever Virus (ASFV). African Swine Fever is a highly lethal disease that poses a significant threat to the pig farming industry, causing severe impacts on the global economy and food security. Therefore, developing effective vaccines is crucial for controlling and preventing the spread of African Swine Fever.

The research focus mentioned in the paper is on the method of preparing LAV by rationally deleting ASFV virulence genes. These genes can be categorized into four types:

1. **Genes related to viral genome replication and transcription**: For example, the gene encoding Thymidine Kinase (TK). Although the deletion of some genes can attenuate the virus's virulence, in most cases, such deletions either result in the virus being too weakened to induce a protective immune response or have little impact on the virus's replication ability.

2. **Genes in the Multigene Family (MGF)**: These genes are located at both ends of the viral genome. Studies have shown that deleting specific combinations of MGF genes (such as six genes including MGF505-1R, MGF360-12L, etc.) can produce completely non-virulent vaccine candidates from highly virulent ASFV strains that provide full protective effects.

3. **Genes involved in the Hemadsorption process**: For example, EP402R (encoding the CD2v protein), which directly participates in the hemadsorption phenomenon. Its deletion can significantly reduce the virus's replication ability in pigs.

4. **Genes with unknown functions**: For example, NL, UK, 9GL, etc. The deletion of these genes also affects the virus's virulence and the safety and efficacy of the vaccine.

In summary, the paper aims to review recent research progress in developing gene-deleted ASFV live-attenuated vaccines and evaluate the impact of different deletion strategies on viral virulence and vaccine protective effects.